An open clinical trial of fluoxetine in the treatment of obsessive-compulsive disorder.

Abstract

In a 9-week open label study, seven outpatients with obsessive-compulsive disorder were treated with fluoxetine, a selective inhibitor of neuronal reuptake of serotonin. After a 7-day placebo washout period, patients were given a dose of 40 mg/day, which was gradually increased to a maximum of 80 mg/day. A significant improvement was found in the symptomatology of patients as measured on the obsessive-compulsive subscale of the Comprehensive Psychopathological Rating Scale (p less than 0.001) and the Clinical Global Impression of severity of illness (p less than 0.01). These findings support the hypothesis that serotonergic antidepressants may be useful in the treatment of obsessive-compulsive disorder and underline the need to carry out double-blind clinical trials to confirm these results.

• Authors: R Fontaine, G Chouinard
• Journal: Journal of clinical psychopharmacology (J Clin Psychopharmacol) Vol. 6 Issue 2 Pg. 98-101 (Apr 1986) ISSN: 0271-0749 [Print] United States
• PMID: 3517083 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Propylamines
• Fluoxetine

Topics

• Adult
• Clinical Trials as Topic
• Female
• Fluoxetine (administration & dosage, adverse effects, therapeutic use)
• Humans
• Male
• Middle Aged
• Obsessive-Compulsive Disorder (diagnosis, drug therapy)
• Propylamines (therapeutic use)
• Psychological Tests